Skip to main content

Junshi Biosciences Announces Full-Year 2019 Financial Results and Business Updates

Written by Customer Service on . Posted in Public Companies.

SHANGHAI, March 30, 2020 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced its audited consolidated annual results of the Company and its subsidiaries for the full-year ended December 31, 2019.
Financial Highlights (IFRS):Total revenue was RMB775 million, mainly due to the sales of toripalimab since its commercialization in February 2019.Due to continued investment in research and development (“R&D”), our R&D expenses were RMB946 million, representing a 75.8% increase from that in 2018. With constant progress in key clinical trials and the introduction of co-R&D and license-in projects, the Company’s R&D pipeline expanded to small molecule drugs and antibody drug conjugates.Selling and distribution expenses were RMB320 million, mainly due to the launch and commercialization of toripalimab.Total comprehensive expense was RMB741 million, representing a slight increase from RMB715 million in 2018, mainly benefits from the contribution of toripalimab sales, but offset by the increase in R&D expenses and administrative expenses.Net cash from financing activities was RMB594 million, principally attributable to net cash from the exercise of over-allotment option of H shares amounting RMB404 million in our initial public offering of H shares on The Stock Exchange of Hong Kong Limited.Net cash used in investing activities was RMB952 million, mainly due to (1) the Lingang Production Base’s construction. The Lingang Production Base is expected to enhance our current production capacity by ten times; and (2) diversification of our R&D pipeline and expansion to small molecule drugs and ADCs through equity investment.Business Highlights

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.